| Literature DB >> 28546915 |
Su Ryon Shin1,2, Tugba Kilic1,2,3, Yu Shrike Zhang1,2, Huseyin Avci1,2,4, Ning Hu1,2,5, Duckjin Kim1,2, Cristina Branco1,2,6, Julio Aleman1,2, Solange Massa1,2,7, Antonia Silvestri1,2,6, Jian Kang1,2,6, Anna Desalvo1,2, Mohammed Abdullah Hussaini8, Su-Kyoung Chae1,2, Alessandro Polini1,2, Nupura Bhise1,2, Mohammad Asif Hussain8, HeaYeon Lee9, Mehmet R Dokmeci1,2, Ali Khademhosseini1,2,10,11.
Abstract
Development of an efficient sensing platform capable of continual monitoring of biomarkers is needed to assess the functionality of the in vitro organoids and to evaluate their biological responses toward pharmaceutical compounds or chemical species over extended periods of time. Here, a novel label-free microfluidic electrochemical (EC) biosensor with a unique built-in on-chip regeneration capability for continual measurement of cell-secreted soluble biomarkers from an organoid culture in a fully automated manner without attenuating the sensor sensitivity is reported. The microfluidic EC biosensors are integrated with a human liver-on-a-chip platform for continual monitoring of the metabolic activity of the organoids by measuring the levels of secreted biomarkers for up to 7 d, where the metabolic activity of the organoids is altered by a systemically applied drug. The variations in the biomarker levels are successfully measured by the microfluidic regenerative EC biosensors and agree well with cellular viability and enzyme-linked immunosorbent assay analyses, validating the accuracy of the unique sensing platform. It is believed that this versatile and robust microfluidic EC biosensor that is capable of automated and continual detection of soluble biomarkers will find widespread use for long-term monitoring of human organoids during drug toxicity studies or efficacy assessments of in vitro platforms.Entities:
Keywords: electrochemical biosensors; electrode regeneration; microfluidic; organ‐on‐a‐chip; secreted biomarkers
Year: 2017 PMID: 28546915 PMCID: PMC5441508 DOI: 10.1002/advs.201600522
Source DB: PubMed Journal: Adv Sci (Weinh) ISSN: 2198-3844 Impact factor: 16.806
Figure 1Detection principle of the label‐free EC biosensing system by using microelectrode. a) A photograph of the fabricated microelectrode having RE (Ag), WE (Au), and CE (Au). b) AFM image of the bare WE surface. c) A schematic illustration for immobilization of antibody using SPV on the surface of the microelectrodes. d) Schematic of charge transfer after antigen binding upon antibody–antigen binding for [K3Fe(CN)6]3−/4− redox process. e) Nyquist plots obtained from measurements before and after the deposition of each layer (SAM, SPV, biotinylated anti‐albumin, media blocking). f) Selectivity study of albumin biosensor showing the effect of media incubation (left side from dotted line). GST‐α, albumin, and CK‐MB incubations on the GST‐α biosensor represented showing the obtained normalized R ct values (right side from dotted line). g) Nyquist plots drawn for different standard human albumin concentrations. h) Calibration curve for human albumin plotted according to the normalized R ct (R ct antigen/R ct media) values.
Figure 2Off‐chip optimization of microelectrode regeneration. a) Schematic illustration of the microelectrode regeneration method with cleaning solution and application of electrical sweep potential. b) Nyquist plots drawn before and after regeneration of the microelectrode. c) Change in R ct value before and after regeneration process represented by histograms with error bars (n = 3). AFM images of the microelectrode surface of d) after antigen immobilization and e) after regeneration. f) SEM image of regenerated microelectrode surface. EDX analysis of the spot shown by red arrow in SEM image. g) Schematic illustration of the microelectrode having different Au layer thickness, 150 and 500 nm. h)The peak current (I pA (A)) at 0.16 V after repeated regeneration of the microelectrodes with two different Au layer thickness (150 and 500 nm) (n = 3). i) AFM image of 25 times regenerated microelectrode surface. j) Histograms with error bars showing the change of RMS roughness (n = 3) and k) thickness of bare, 1 time, and 25 times regenerated microelectrode surfaces (n = 3).
Figure 3Design, fabrication, and control of the automated microfluidic EC biosensor. a) Photograph of the EC microfluidic chip bonded with microelectrode. b) Labeling of the microfluidic channels and the valves with corresponding flowing solutions for fully automated biosensing measurements. c) Three‐layered microfluidic chip consisted of microfluidic channel, thin membrane, and valve channel layer. d) Schematically represented working principle to open and close the microfluidic channel by the push‐down thin membrane according to gas pressure. e) Time‐lapsed picture of microfludic EC chip showing the color changes in the main channel for PBS and detection chamber upon opening and closing of the valves. f) Time required for changing the chemicals at the electrode area demonstrated by using food dyes. g) Measured flow rates at different channels under various gas pressures (n = 3).
Figure 4On‐chip optimization of regeneration method and sensing performance of repeated regeneration under automated manner. a) Nyquist plots for different standard human albumin concentrations. b) Calibration curve for human albumin plotted according to the normalized R ct (R ct antigen/R ct media) values (n = 3). c) The resulting regeneration efficiencies as recovered current rate which was obtained from the normalized peak current (I pA (A)) at 0.16 V with and without flow conditions in microfluidic chip. d) Schematics of regeneration process with and without flow conditions in microfluidic chip. e) The peak current measured at a potential of 0.16 V after repeated regeneration of the microelectrodes. Histograms showing f) the RMS roughness data (n = 3) and g) thickness recorded based on AFM measurements for off‐chip and on‐chip cleaning conditions (n = 3). h) AFM image of the microelectrode surface after on‐chip cleaning. i) Change in normalized R ct value of antigen detection according to several number of automated regeneration (n = 3).
Figure 5On‐chip detection of biomarkers secretion from primary hepatocyte bioreactor construct upon drug treatment. a) Sealed and primary hepatocyte spheroid patterned bioreactor with magnified view of incubation chamber and microscope image of a printed spheroid. b) Continual EC measurements of albumin (n = 3) and c) GST‐α production rate in primary hepatocyte bioreactor with control, 5 × 10−3 and 10 × 10−3 m APAP exposure conditions (n = 3). d) Live/dead staining for control, 5 × 10−3 m APAP exposed and 10 × 10−3 m APAP exposed primary hepatocyte spheroids in bioreactor at days 1, 3, 5, and 7. e) Schematic diagram of the microfluidic EC biosensing system integrated with organ‐on‐a‐chip for continual monitoring of a target biomarker by automated manner. f) Automatic continual EC measurements of albumin and GST‐α production rate in primary hepatocyte bioreactor without drug treatment.